Fig. 4From: A pancancer analysis of the carcinogenic role of receptor-interacting serine/threonine protein kinase-2 (RIPK2) in human tumoursMutation frequency of RIPK2 in malignant tumours. The figure showed that RIPK2 was the main type of Amplification in BRCA, UCS and PRAD, the main type of Mutation in UCEC, and the main type of Deep deletion in DLBCBack to article page